Ambit Biosciences Receives $30,000,000 Series D Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f1d5c08a-248e-4748-869e-1f8a9ea43a5a&Preview=1 -
Date
6/10/2011 -
Company Name
Ambit Biosciences -
Mailing Address
4215 Sorrento Valley Blvd. San Diego, CA 92121 -
Company Description
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. -
Website
http://www.ambitbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series D -
Proceeds Purposes
This recent capital raise will allow us to continue the clinical development of our lead product candidate, AC220, which is currently in a Phase 2 pivotal trial in Acute Myeloid Leukemia. This financing also provides for the continued development of our other two clinical assets, AC430 and AC480, both of which are in Phase 1 trials. -
M&A Terms
-
Venture Investor
Apposite Capital -
Venture Investor
OrbiMed -
Venture Investor
Forward Ventures -
Venture Investor
MedImmune Ventures -
Venture Investor
Growthworks Capital -
Venture Investor
Roche Venture Fund -
Venture Investor
GeneChem -
Venture Investor
GIMV -
Venture Investor
Radius Ventures -
Venture Investor
NovaQuest -
Venture Investor
Horizon Technology Finance
